We are part of the CSL Limited group of companies. See how we're Driven by Our Promise.
We collaborate with rare disease organizations to promote quality medical care and services.
We offer a variety of support programs and activities for the patients we serve.
We also aim to make sure that nothing holds you back from getting the therapies you need.
Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise.
A clinical trial is a research study that is done to find out if medical treatments can improve people’s health.
We work every day as if someone’s life depends on it, because it does.
We manufacture products to treat a number of rare diseases.
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL Behring.
Ready to Return to Working On-Sites
Ahead of all employees soon returning to working on-sites, CSL CEO Paul Perreault puts in time at the company’s Pennsylvania …
CSL CEO Paul Perreault on Australia
“It is personal. My headquarters are in Melbourne, I want to get back,” Perreault tells the Australian Financial Review’s BOS…
A Pathway Out of the Pandemic
CSL CEO Paul Perreault talks vaccines, business confidence and innovation at a University of Melbourne event.
Speed Meeting Global Colleagues
In a year with very little business travel, CSL employees found a way to meet across the miles.
CSL CEO Gives Keynote at Patient Event
The company has maintained its focus on patients amid the challenges of the pandemic, CSL Limited CEO Paul Perreault said.
Explainer: What Is PhRMA?
CSL CEO Paul Perreault recently joined the board of the Pharmaceutical Research and Manufacturers of America.
Industry Partnership Fuels Research, Advocacy
PhRMA membership expands CSL Behring’s opportunity for cooperation between industry leaders.
CSL CEO at Utah Life Sciences Summit
At biotech event, Paul Perreault will talk about the company’s COVID-19 response – including a potential treatment now in a c…
Watch Online: CSL CEO at a White House Roundtable
Perreault made the case for a plasma-based hyperimmune to treat COVID-19.
CEO Paul Perreault at White House Roundtable
Perreault, representing the plasma industry, said an antibody treatment depends on additional donations from recovered patien…
CSL CEO: Don't Rush the COVID-19 Vaccine
Joining scientists and medical experts, Perreault urges rigor, precision and the necessary time to ensure vaccine safety.
Dealing With Challenges Head-On
CSL Limited CEO Paul Perreault offers a message of encouragement during the COVID-19 pandemic.
Popular search terms:
Americas
Asia Pacific
Europe
This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of these cookies. To learn more about how we use and manage cookies, see our Privacy Policy and Cookie Policy.
.jpeg?h=900&iar=0&w=1600&cropregion=0,0,1600,900&hash=14848A3B460458A376D1D287A984F26C)
